

## Administrative Policy Statement INDIANA MEDICARE ADVANTAGE

Policy Name		Policy Number	Date Effective
COVID-19 Vaccination		PAD-0081-IN-MAP	12/18/2020
Policy Type			
Medical	<b>ADMINISTRATIVE</b>	Pharmacy	Reimbursement

Administrative Policy Statements prepared by CareSource and its affiliates are derived from literature based on and supported by clinical guidelines, nationally recognized utilization and technology assessment guidelines, other medical management industry standards, and published MCO clinical policy guidelines. Medically necessary services include, but are not limited to, those health care services or supplies that are proper and necessary for the diagnosis or treatment of disease, illness, or injury and without which the patient can be expected to suffer prolonged, increased or new morbidity, impairment of function, dysfunction of a body organ or part, or significant pain and discomfort. These services meet the standards of good medical practice in the local area, are the lowest cost alternative, and are not provided mainly for the convenience of the member or provider. Medically necessary services also include those services defined in any Evidence of Coverage documents, Medical Policy Statements, Provider Manuals, Member Handbooks, and/or other policies and procedures.

Administrative Policy Statements prepared by CareSource and its affiliates do not ensure an authorization or payment of services. Please refer to the plan contract (often referred to as the Evidence of Coverage) for the service(s) referenced in the Administrative Policy Statement. If there is a conflict between the Administrative Policy Statement and the plan contract (i.e., Evidence of Coverage), then the plan contract (i.e., Evidence of Coverage) will be the controlling document used to make the determination.

According to the rules of Mental Health Parity Addiction Equity Act (MHPAEA), coverage for the diagnosis and treatment of a behavioral health disorder will not be subject to any limitations that are less favorable than the limitations that apply to medical conditions as covered under this policy.

### Table of Contents

Administrative Policy Statements .....	1
A. Subject.....	2
B. Background.....	2
C. Definitions .....	3
D. Policy .....	3
E. Conditions of Coverage.....	5
F. Related Policies/Rules .....	6
G. Review/Revision History .....	6
H. References .....	6



## A. Subject

### COVID-19 Vaccination

## B. Background

The 2019 novel coronavirus, also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causes the disease known as coronavirus disease 2019 (COVID-19). The Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for two vaccines for the prevention of COVID-19: Pfizer-BioTech and Moderna as of December 2020. Both vaccines are offered as a two-dose series. The EUA allows the vaccines to be widely distributed in the United States.

The Advisory Committee on Immunization Practices (ACIP) has issued interim recommendations for the use of Pfizer-BioNTech and Moderna COVID-19 vaccines for the prevention of COVID-19 in the U.S. The interim recommendations are derived from the EUA of the vaccines, other data sources, general best practice guidelines for immunization, and expert opinion. Considerations will be updated as additional information becomes available or if additional vaccine products are authorized.

The purpose of this policy is to provide background on the use of the vaccines in accordance with the ACIP interim recommendations and the EUA fact sheets of the available COVID-19 vaccines.

The following professional society's recommendations are derived from the latest guidelines and scientific based literature available.

Advisory Committee on Immunization Practices (ACIP):

- **Pfizer COVID-19 Vaccine:** Vaccination with the Pfizer-BioNTech COVID-19 vaccine consists of 2 doses (30 µg, 0.3 mL each) administered intramuscularly, 3 weeks apart. On December 12, 2020, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of the Pfizer-BioNTech COVID-19 vaccine in persons aged ≥16 years for the prevention of COVID-19. The recommendation for the Pfizer-BioNTech COVID-19 vaccine should be implemented in conjunction with ACIP's interim recommendation for allocating initial supplies of COVID-19 vaccines. The ACIP recommendation for the use of the Pfizer-BioNTech COVID-19 vaccine under EUA is interim and will be updated as additional information becomes available.
  - Before vaccination, the EUA Fact Sheet should be provided to recipients and caregivers. Providers should counsel Pfizer-BioNTech COVID-19 vaccine recipients about expected systemic and local reactogenicity.
  - Additional clinical considerations, including details of administration and use in special populations (e.g., persons who are pregnant or immunocompromised or who have severe allergies) are available at [www.cdc.gov](http://www.cdc.gov).
- **Moderna COVID-19 Vaccine:** On December 19, 2020, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of the Moderna COVID-19 vaccine in persons aged ≥18 years for the prevention of COVID-19. Use of all COVID-19 vaccines authorized under an EUA, including the Moderna



COVID-19 vaccine, should be implemented in conjunction with ACIP's interim recommendations for allocating initial supplies of COVID-19 vaccines (3). The ACIP recommendation for the use of the Moderna COVID-19 vaccine under EUA is interim and will be updated as additional information becomes available. The interim recommendation and clinical considerations are based on use of the Moderna COVID-19 vaccine under an EUA and might change as more evidence becomes available.

- Before vaccination, the EUA Fact Sheet should be provided to recipients and caregivers. Providers should counsel Moderna COVID-19 vaccine recipients about expected local and systemic reactogenicity.
- The Moderna COVID-19 vaccine is not interchangeable with other COVID-19 vaccine products; the safety and efficacy of a mixed-product series have not been evaluated.
- ACIP does not state a product preference; a person may receive any recommended COVID-19 vaccine series. However, persons should complete the series with the same COVID-19 product they received for the first dose.
- Additional clinical considerations, including details of administration and use in special populations (e.g., persons who are pregnant, immunocompromised or who have a history of severe allergic reactions) are available at [www.cdc.gov](http://www.cdc.gov).

**Note: Additional Vaccines** – Newly developed vaccines are still moving through the clinical trial process before submission for regulatory approval. CareSource is closely monitoring FDA approval of these vaccines.

### C. Definitions

- **Emergency Use Authorization (EUA)** – A mechanism to facilitate the availability and use of medical countermeasures, including vaccines, during public health emergencies.
- **Vaccine Adverse Event Reporting System (VAERS)** – A national early warning system to detect possible safety problems in vaccines used in the United States.
- **Immunization Information System (IIS)** – A confidential, population-based, computerized databases that record all immunization doses administered by participating providers to persons residing within a specific geopolitical area.

### D. Policy

- I. COVID-19 vaccination providers participating in the Centers for Disease Control and Prevention (CDC) COVID-19 Vaccination Program are required to sign a CDC COVID-19 Vaccination Program Provider Agreement. Providers are responsible for adhering to all requirements outlined in the agreement.
- II. Providers must follow the prioritization schedule as determined by the state's and/or the Department of Health's plan for distributing the vaccines (e.g., Phase 1a includes healthcare personnel, Phase 1b includes persons ≥75 years of age, etc.):
  - A. COVID-19 vaccine providers are prohibited from selling USG-purchased COVID-19 vaccine, receiving any inducement (whether direct or indirect) for vaccinating (or providing COVID-19 vaccine to be used for vaccinating) any individual who is



not currently eligible to receive COVID-19 vaccine as a member of a group currently authorized under prioritization specified by CDC/ACIP, the state/territory's governor or other relevant public health authority, or otherwise diverting COVID-19 vaccine from the CDC COVID-19 Vaccination Program.

- III. The member's age must be within the age group that is authorized to receive the COVID-19 vaccination:
  - A. Pfizer-BioNTech: age 16 years or greater; and
  - B. Moderna: age 18 years or greater.
- IV. The vaccination provider must follow the vaccine schedule as outlined in the EUA fact sheet:
  - A. Pfizer-BioNTech: 2 doses, 21 days apart; and
  - B. Moderna: 2 doses, 28 days apart.
- V. The provider must communicate to the individual receiving the vaccine or their caregiver, information consistent with the "Fact Sheet for Recipients and Caregivers" prior to receiving the vaccine.
- VI. The vaccination provider must follow the storage and handling instruction of the vaccine as outlined in the EUA fact sheet of the individual vaccine.
- VII. The vaccination provider must include vaccination information in the state/local jurisdiction's Immunization System (IIS) or other designated system:
  - A. All COVID-19 vaccination providers must report COVID-19 vaccine inventory daily into VaccineFinder. In some jurisdictions, providers may report vaccine inventory to the jurisdiction's IIS for the jurisdiction to upload into VaccineFinder.
  - B. COVID-19 vaccination providers must document vaccine administration in their medical record systems within 24 hours of administration, and use their best efforts to report administration data to the relevant system for the jurisdiction (i.e., IIS) as soon as practicable and no later than 72 hours after administration.
- VIII. The vaccination provider is responsible for mandatory reporting of any significant adverse events to the Vaccine Adverse Event Reporting System (VAERS).
  - A. The following adverse events are required to be reporting in addition to any other events if later revised by the CDC:
    - 1. Vaccine administration errors, whether or not associated with an adverse event (AE);
    - 2. Serious AEs regardless of causality. Serious AEs are defined as:
      - a. Death;
      - b. A life-threatening AE;
      - c. Inpatient hospitalization or prolongation of existing hospitalization;
      - d. A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions;
      - e. A congenital anomaly/birth defect;



- f. An important medical event that based on appropriate medical judgement may jeopardize the individual and may require medical or surgical intervention to prevent one of the outcomes listed above;
  - g. Cases of Multisystem Inflammatory Syndrome;
  - h. Cases of COVID-19 that result in hospitalization or death.
- A. Providers are encouraged to report to VAERS any additional clinically significant adverse event following vaccination, even if they are not sure if vaccination caused the event.
  - B. Providers should also report any additional select AEs and/or any revised safety reporting requirements per FDA's conditions of authorized use of vaccine(s) throughout the duration of any COVID-19 Vaccine being authorized under an EUA.

#### IX. Claims, Reimbursement and Member Cost Share

- A. All FDA-authorized COVID-19 vaccines will be covered at no cost for members during the public health emergency.
- B. Vaccine providers must administer the vaccine regardless of the member's ability to pay or verify health insurance coverage status.
- C. Vaccine providers may not seek any reimbursement, including through balance billing, from the vaccine recipient.
- D. Vaccine providers may seek appropriate reimbursement from a program or plan that covers COVID-19 Vaccine administration fees for the vaccine recipient.
- E. Providers may bill the CareSource medical benefit through our standard claims process.
- F. Pharmacies should submit claims through their pharmacy claims platform through our pharmacy benefits manager, Express Scripts.

#### E. Conditions of Coverage

The COVID-19 vaccines are not covered on the CareSource Medicare Advantage benefit plan and are only covered with Original Medicare per Centers of Medicare and Medicaid guidance. Please submit billing information directly to Original Medicare.

#### HCPCS and CPT Codes:


##### Pfizer-BioNTech COVID-19 Vaccine

- o CPT91300 – vaccine
- o 0001A – 1<sup>st</sup> dose administration
- o 0002A – 2<sup>nd</sup> dose administration

##### Moderna COVID-19 Vaccine

- o 91301 – vaccine
- o 0011A – 1<sup>st</sup> dose administration
- o 0012A – 2<sup>nd</sup> dose administration

Quantity Limit: Only one vaccine is allowed per member. Two doses per vaccine.  
Quantity limit is subject to change as more vaccines become available for use.



## F. Related Policies/Rules

COVID-19 Vaccine Reimbursement Policy

## G. Review/Revision History

DATES		ACTION
Date Issued	12/18/2020	New policy
Date Revised		
Date Effective	12/18/2020	
Date Archived		

## H. References

1. Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(50):1922-1924.
2. Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020. *MMWR Morb Mortal Wkly Rep.* 2021;69(5152):1653-1656.
3. Centers for Disease Control and Prevention (CDC). (2021). Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19) in Individual 16 Years of Age or Older [Fact sheet].
4. Centers for Disease Control and Prevention (CDC). (2020). Emergency Use Authorization (EUA) of the Moderna COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19) in Individual 18 Years of Age or Older [Fact sheet].

**The Administrative Policy Statement detailed above has received due consideration as defined in the Administrative Policy Statement Policy and is approved.**